Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation.

Trial Profile

Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BLAST
  • Sponsors BIOrest
  • Most Recent Events

    • 19 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Sep 2010 Primary endpoint 'In-stent late loss' has not been met, according to results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 21 Sep 2010 Top-line results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top